CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. […]
Oppenheimer restated their outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a report published on Thursday morning, Benzinga reports. Oppenheimer currently has a $102.00 price target on the stock. A number of other research firms have also recently weighed in on CRSP. Citigroup increased their price target on CRISPR Therapeutics from […]
Integral Health Asset Management LLC acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 100,000 shares of the company’s stock, valued at approximately $4,523,000. Integral Health Asset Management LLC owned 0.13% of […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.13) by $1.15, Briefing.com reports. CRISPR Therapeutics had a negative return on equity of 21.62% and a negative net margin of 240.84%. The firm had […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price traded up 6.9% during trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $51.78 and last traded at $51.68. 274,585 shares changed hands during mid-day trading, a decline of 77% from the average session volume of […]